Julio Rosenstock, MD
Enriched profileDirector, Dallas Diabetes Research Center at Medical City; Clinical Professor of Medicine, UT Southwestern Medical Center · Dallas Diabetes Research Center at Medical City
Julio Rosenstock is Director, Dallas Diabetes Research Center at Medical City; Clinical Professor of Medicine, UT Southwestern Medical Center at Dallas Diabetes Research Center at Medical City. OpenAlex indexes 693 publications with 69,666 citations (h-index 121); ClinicalTrials.gov lists 3 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Endocrinology, Diabetes & Metabolism profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Julio Rosenstock, MD, is Director, Dallas Diabetes Research Center at Medical City. The public record shows 693 publications with 69,666 citations (h-index 121), centered on Diabetes Treatment and Management, Diabetes Management and Research, Metabolism, Diabetes, and Cancer. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 23 companies.
- Most recent indexed publication: 2026 · Diabetes, obesity & metabolism
- Top research focus: Diabetes Treatment and Management
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 23 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 105 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 326.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks
Sponsor: Elcelyx Therapeutics, Inc.
Industry payments
Updated 27 Aug 2026
23 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SANOFI-AVENTIS U.S. LLCProgram year20251 payment$34,567openpaymentsdata.cms.gov ↗
- Novo Nordisk ASProgram year202510 payments$34,209openpaymentsdata.cms.gov ↗
- SANOFI US SERVICES INC.Program year20255 payments$25,312openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Biguanide (metformin)100%Metformin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
66 congress contributions (2012–2025) across AACE, ADA, ASCO, ENDO per OpenAlex. The most recent:
- 1863-LB: The Confidence Trial—Efficacy/Safety of Combining Finerenone with Empagliflozin in People with Chronic Kidney Disease and Type 2 Diabetes
ADA Scientific Sessions
ADA2025Co-authorLate-breaking
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O Trial.
Diabetes, obesity & metabolism
Article2026 - Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed-Dose Titration of Weekly Insulin Efsitora in Insulin-Naïve Type 2 Diabetes.
Diabetes, obesity & metabolism
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes6,648 citations2016
- 02Once-Weekly Semaglutide in Adults with Overweight or Obesity4,582 citations2021
- 03Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes1,897 citations2021
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/velocity-clinical_julio-rosenstock-md-face-is-an-author-activity-7159263862423195648-JfxK
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Other
velocityclinical.com/julio-rosenstock-md-face-featured-on-ada-diabetes-core-update-podcast
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →velocityclinical.com ↗ - X / Twitter
x.com/velocitycr/status/1887583297770786992
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Costa Rica School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dallasdiabetes.com ↗ - Fellowship in Endocrinology and Diabetes
Royal Postgraduate Medical School, Hammersmith Hospital, London, UK
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dallasdiabetes.com ↗ - Fellowship in Endocrinology and Diabetes
University of Texas Southwestern Medical Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dallasdiabetes.com ↗ - Board certified
Internal Medicine, and Endocrinology and Metabolism
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dallasdiabetes.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →velocityclinical.com ↗
Editorial & leadership roles
journal and society appointments- Associate Editor
Diabetes Care (American Diabetes Association journal)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →diabetesjournals.org ↗ - Editorial Board member
Practical Diabetology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗ - Editorial Board member
Cardiovascular Diabetology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →velocityclinical.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oramed.com ↗
- Principal Investigator / Site Director
Velocity Clinical Research, Dallas, TX
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →velocityclinical.com ↗
Media & interviews
press, podcasts and appearances- Featured guest on the American Diabetes Association's "Diabetes Core Update" podcast
discussing a JAMA article on tirzepatide vs. insulin lispro added to basal insulin in type 2 diabetes …
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →velocityclinical.com ↗ - Research on once-weekly basal insulin icodec featured on the New England Journal of Medicine homepage
including an accompanying summary video
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →velocityclinical.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH